362 Comparison of PREDICT Score to Oncotype Dx Score in Early Invasive Breast Cancer

Abstract Aim The PREDICT score is used to help define decisions about benefits of chemotherapy in early invasive breast cancer. With a PREDICT score of 5% or more chemotherapy should be considered, 3% to 4% is a borderline decision and less than 3% chemotherapy is not pursued. We set out to compare the PREDICT score to Oncotype Dx recurrence score (RS), which predicts chemotherapy benefit based on 21-gene breast cancer assay. Method Data for patient and tumour characteristics, and treatment choice was collected from electronic patient records of 98 patients who had an RS score done between February 2017-September 2020. This data was then compared to the patients’ PREDICT scores. Results 98 patients were analysed with 2 excluded due to having nodal macro-metastases. Mean patient age was 53 years with an average tumour size of 27mm. 31/96 (32%) patients had a PREDICT score ≥5%, with 21/31 (68%) having a low RS score (<26). 57/96 (59%) patients had a PREDICT score of 3-4%, with 40/57 (70%) having a low RS score. 8/96 (8%) patients had a PREDICT score of < 3%, with 7/8 (88%) having a low RS score. Additionally, 7/8 (88%) patients in this group were pre-menopausal. Conclusions 68% of patients in the ≥5% PREDICT group had a low RS score and so have avoided chemotherapy. In the 3-4% group, approximately 1 in 3 tested were shown to have a chemotherapy benefit. In the <3% group most patients were pre-menopausal, and chemotherapy was safely avoided. A bigger dataset and comparison to other health boards is required.

Download Full-text

Breast cancer specific survival in patients with node-positive hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.6575 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 6575-6575

Author(s):

Megan Roberts ◽

Valentina I. Petkov ◽

Dave P. Miller ◽

Steven Shak ◽

Nadia Howlader ◽

...

Keyword(s):

Breast Cancer ◽

Invasive Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Breast Cancer Specific Survival ◽

Seer Database ◽

Cancer Specific Survival ◽

Hormone Receptor Positive ◽

Oncotype Dx Recurrence Score

Download Full-text

A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.542 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 542-542

Author(s):

Takeo Fujii ◽

Hiroko Masuda ◽

Yee Chung Cheng ◽

Fei Yang ◽

Aysegul A. Sahin ◽

...

Keyword(s):

Breast Cancer ◽

Invasive Breast Cancer ◽

Recurrence Score ◽

Recurrence Risk ◽

Gene Signature ◽

Oncotype Dx ◽

Node Negative ◽

Er Positive ◽

Chemoendocrine Therapy ◽

Oncotype Dx Recurrence Score

542 Background: The TAILORx trial demonstrated that adjuvant endocrine and chemoendocrine therapies had similar efficacy in patients with hormone receptor-positive, HER2-negative, node-negative breast cancer with an Oncotype DX recurrence score (RS) of 11-25. However, a predictive strategy is needed to identify patients with intermediate RS who may benefit from adjuvant chemoendocrine therapy. Curebest 95GC Breast (95GC) is a 95-gene signature that can stratify patients into two groups with high (95GC-H) and low (95GC-L) groups to predict the risk of recurrence. Our primary objective was to show that 95GC can classify patients with intermediate RS into binary recurrence risk groups. Methods: Patients with ER-positive, HER2-negative, node-negative invasive breast cancer and RS 11-30 who underwent definitive surgery and adjuvant endocrine therapy were included. RNA was derived from archived formalin-fixed, paraffin-embedded samples, and 95GC was calculated as reported previously. The Fisher exact and Brunner-Munzel tests were used to compare variables between 95GC groups. A Kaplan-Meier estimate with a log-rank test was used for recurrence-free survival (RFS) analysis. Results: The analysis included 178 patients from five institutions. The 5-year RFS rate in patients with RS 18-30 was higher in the 95GC-L group (n = 129, 96.3%) than in the 95GC-H group (n = 49, 90.9%; p = 0.002), which was consistent with results in an independent Japanese population (n = 224; p < 0.001). RFS rates significantly differed between the groups among patients with RS 11-25 as well (95GC-L, 97.4%; 95GC-H, 87.1%; p = 0.001). RFS rates did not differ between patients with RS 18-25 (94.8%) and those with RS 26-30 (93.8%; p = 0.33). Conclusions: 95GC can predict recurrence risk in patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS. Further prospective retrospective studies in the TAILORx population are warranted to confirm that 95GC can identify patients who may benefit from adjuvant chemoendocrine therapy.

Download Full-text